Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia

References

• Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636–648.
   PubMed Web of Science ®Google Scholar
• Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis. 2017;8(1):4–11.
   PubMed Web of Science ®Google Scholar
• Fras Z, Mikhailidis DP. Have we learnt all from IMPROVE-IT? Part I. Core results and subanalyses on the effects of ezetimibe added to statin therapy related to age, gender and selected chronic diseases (kidney disease, diabetes mellitus and non-alcoholic fatty liver disease). Curr Vasc Pharmacol. 2020 Jul 27;18. Epub ahead of print. PMID: 32720602. DOI:10.2174/1570161118999200727224946.
   Google Scholar
• Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–464.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(125): e1082–e143.
   PubMedGoogle Scholar
• Ferreira AM, Marques da Silva P. Defining the place of ezetimibe/atorvastatin in the management of hyperlipidemia. Am J Cardiovasc Drugs. 2017;17(3):169–181.
   PubMed Web of Science ®Google Scholar
• Banach M, Penson PE, Vrablik M, et al. ACS EuroPath central & South European countries project. Optimal use of lipidlowering therapy after acute coronary syndromes: a position paper endorsed by the international lipid expert panel (ILEP). Pharmacol Res. 2021 Feb 17;166:105499. Epub ahead of print. PMID: 33607265.
   PubMed Web of Science ®Google Scholar
• Bhagavathula AS, Aldhaleei WA, Al Matrooshi NO, et al. Efficacy of statin/ezetimibe for secondary prevention of atherosclerotic cardiovascular disease in Asian populations: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2020;40(9):809–826.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al., Meta-analysis of the cholesterol lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23(8): 2009–2026.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin. 2011;27(6):1191–1210.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT investigators. ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, et al. JUPITER: major implications for vascular risk assessment. Curr Med Res Opin. 2009;25(1):133–137.
   PubMed Web of Science ®Google Scholar
• Faergeman O, Hill L, Windler E, et al. ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219–228.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Spinas GA, et al. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? [Internet]. Int J Clin Pract. 2009;63(3):478–485.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003;92(2):152–160.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76.
   PubMed Web of Science ®Google Scholar
• Athyros V, Kakafika A, Tziomalos K, et al. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des. 2009;15(5):479–489.
   PubMed Web of Science ®Google Scholar
• Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325–330.
   Google Scholar
• Paraskevas KI, Mikhailidis DP, Veith FJ. Optimal statin type and dosage for vascular patients. J Vasc Surg. 2011;53(3):837–844.
   PubMed Web of Science ®Google Scholar
• Quirk J, Thornton M, Kirkpatrick P. Rosuvastatin calcium. Market analysis. Nat Rev Drug Discov. 2003;2(10):769–770.
   PubMedGoogle Scholar
• Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin treated patients in a multinational clinical trial program. Cardiology. 2007;107(4):433–443.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Mikhailidis DP. Should we consider ezetimibe to reach even lower LDL-C targets? Curr Med Res Opin. 2015;31(3):459–460.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des. 2013;19(17):3107–3114.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on c-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103(3):369–374.
   PubMed Web of Science ®Google Scholar
• Hwang I, Park SI, Lee SH, et al. Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects. Transl Clin Pharmacol. 2018;26(1):16–24.
   PubMedGoogle Scholar
• Kang WY, Seong SJ, Ohk B, et al., Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects. Int J Clin Pharmacol Ther. 2018;56(1): 43–52.
   PubMed Web of Science ®Google Scholar
• Nishida C, Matsumoto Y, Fujimoto K, et al. The bioequivalence and effect of food on the pharmacokinetics of a fixed-dose combination tablet containing rosuvastatin and ezetimibe in healthy Japanese subjects. Clin Transl Sci. 2019;12(6):704–712.
   PubMedGoogle Scholar
• Hong SJ, Jeong HS, Ahn JC, et al., A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: i-ROSETTE (Ildong rosuvastatin & ezetimibe for hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2): 226–41.e4.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kim SH, Yoon YW, et al., Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter randomized study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5): 371–382.
   PubMed Web of Science ®Google Scholar
• Yang YJ, Lee SH, Kim BS, et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk. Clin Ther. 2017;39(1):107–117.
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study). Am J Cardiol. 2011;108(4):523–530.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Tocci G, Fogacci F, et al. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother. 2020;21(5):531–539.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study). Am J Cardiol. 2007;99(5):673–680.
   PubMed Web of Science ®Google Scholar
• Kim W, Yoon YE, Shin SH, et al. Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2018;40(6):993–1013.
   PubMed Web of Science ®Google Scholar
• Bandaru SP. Stability indicating liquid chromatographic method for the simultaneous determination of rosuvastatin and ezetimibe in pharmaceutical formulations. Adv Pharm Bull. 2014;4(4):405–411.
   PubMedGoogle Scholar
• Torimoto K, Okada Y, Mori H, et al., Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12(1): 137.
   PubMedGoogle Scholar
• Klein D, Hurley LB, Quesenberry CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30(5):471–477.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17(17):2479–2486.
   PubMed Web of Science ®Google Scholar
• Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6(1):15.
   PubMedGoogle Scholar
• Saeedi R, Johns K, Frohlich J, et al. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14(1):57.
   PubMedGoogle Scholar
• Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20mg plus ezetimibe 10mg vs. simvastatin 40 or 80mg plus ezetimibe 10mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014;232(1):86–93.
   PubMed Web of Science ®Google Scholar
• Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J. 2015;56(3): 278–285.
   PubMed Web of Science ®Google Scholar
• Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013;18(1):5–12.
   PubMed Web of Science ®Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54(5):472–477.
   PubMed Web of Science ®Google Scholar
• Plans-Rubió P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs. 2010;10(6):369–382.
   PubMed Web of Science ®Google Scholar
• Lee J, Hwang YC, Lee WJ, et al. Comparison of the efficacy and safety of rosuvastatin/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study. Diabetes Ther. 2020;11(4):859–871.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/nonalcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71(4): 17–32.
   PubMedGoogle Scholar
• Bove M, Fogacci F, Cicero AFG. Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2017;13(10):1099–1104.
   PubMed Web of Science ®Google Scholar